392 related articles for article (PubMed ID: 25350080)
1. Effect of intravesical botulinum neurotoxin-A injection on detrusor hyperreflexia in spinal cord injured patients.
Ge XT; Li YF; Wang Q; Zhao JN
Drug Res (Stuttg); 2015 Jun; 65(6):327-31. PubMed ID: 25350080
[TBL] [Abstract][Full Text] [Related]
2. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
Chen G; Liao L
Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
[TBL] [Abstract][Full Text] [Related]
3. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
[TBL] [Abstract][Full Text] [Related]
4. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity.
Chen SF; Kuo HC
J Formos Med Assoc; 2015 Jul; 114(7):583-9. PubMed ID: 24262922
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
8. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.
Sengoku A; Okamura K; Kimoto Y; Ogawa T; Namima T; Yamanishi T; Yokoyama T; Akino H; Maeda Y
Int J Urol; 2015 Mar; 22(3):306-9. PubMed ID: 25403926
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity.
Alvares RA; Silva JA; Barboza AL; Monteiro RT
Int Braz J Urol; 2010; 36(6):732-7. PubMed ID: 21176280
[TBL] [Abstract][Full Text] [Related]
14. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
15. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity.
Hui C; Keji X; Chonghe J; Ping T; Rubiao O; Jianweng Z; Xiangrong D; Liling Z; Maping H; Qingqing L; Qiuling L; Jiebing H; Tanghai H
Spinal Cord; 2016 Jan; 54(1):46-50. PubMed ID: 26261074
[TBL] [Abstract][Full Text] [Related]
16. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
Álvares RA; Araújo ID; Sanches MD
BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions.
Klaphajone J; Kitisomprayoonkul W; Sriplakit S
Arch Phys Med Rehabil; 2005 Nov; 86(11):2114-8. PubMed ID: 16271557
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type A for refractory neurogenic detrusor overactivity in spinal cord injured patients in Singapore.
Tow AM; Toh KL; Chan SP; Consigliere D
Ann Acad Med Singap; 2007 Jan; 36(1):11-7. PubMed ID: 17285181
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions.
Bagi P; Biering-Sørensen F
Scand J Urol Nephrol; 2004; 38(6):495-8. PubMed ID: 15841785
[TBL] [Abstract][Full Text] [Related]
20. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
